ArticleCureus2025
Splenic Diffuse Red Pulp Small B-cell Lymphoma: A Rare Diagnosis in a Patient With Incidental Abnormal Lymphocytosis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Splenic diffuse red pulp small B-cell lymphoma (SDRPL) is an extremely rare form of non-Hodgkin lymphoma that has an indolent course and is characterized by splenomegaly, lymphocytosis, and hemocytopenia. Lymphomas with villous morphology are rare, with the least common subtype being SDRPL. Therefore, the diagnosis of SDPRL primarily hinges on a rigorous exclusion of other lymphoproliferative disorders, alongside a detailed correlation of histopathological features from bone marrow and spleen tissues, complemented by comprehensive immunophenotypic analysis. Adequate diagnosis is important to guide patient treatment and outcome. Here, we present a case of a 66-year-old male who presented with leukocytosis. At first, the patient was asymptomatic, though a peripheral blood smear revealed abnormal lymphocytes, and the presence of hairy cells led to a misdiagnosis of hairy cell leukemia (HCL), hence, no treatment was administered for six years. Subsequently, the patient was re-diagnosed with a splenic condition resembling a hairy cell variant, which later was found to be SDPRL. After minimal to no response on rituximab monotherapy, the patient was transitioned to cyclophosphamide and eventually to zanubrutinib, with subsequent hematologic improvement. This case underscores the diagnostic complexity of SDRPL, the importance of a multidisciplinary approach in distinguishing it from other splenic lymphomas, and highlights the therapeutic challenges in managing this rare entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.